Stock-based
compensation 439 998 2,298 2,854
Depreciation,
amortization and
patent cost
write-off 352 380 1,032 1,087
-------------------------------------------------------------------------
10,146 15,540 35,354 55,556
-------------------------------------------------------------------------
Loss before
undernoted items (9,993) (15,239) (34,927) (54,311)
Interest income 145 1,021 856 2,585
Interest and bank
charges (109) (26) (181) (150)
Accretion expense (1,243) (1,452) (3,675) (14,568)
Change in fair
value of embedded
derivatives 45 972 145 (898)
Write-down of
third party
asset-backed
commercial paper - - (375) -
Foreign exchange
gain (loss) (216) 565 644 1,184
Other income 276 270 810 987
Share of loss in a
company subject
to significant
influence - - - (327)
Non-controlling
interest - - - 109
-------------------------------------------------------------------------
Net loss ($11,095) ($13,889) ($36,703) ($65,389)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Net loss per share:
Basic and diluted ($0.22) ($
'/>"/>
| SOURCE BELLUS Health Inc. Copyright©2008 PR Newswire. All rights reserved |